Printer Friendly

SYNTRO AND HOECHST TO DEVELOP VACCINES

 SYNTRO AND HOECHST TO DEVELOP VACCINES
 KANSAS CITY/SOMERVILLE, N.J., Feb. 19 /PRNewswire/ -- Syntro


Corporation (NASDAQ:SYNT), Hoechst-Roussel Agri-Vet Company and Hoechst Veterinar GmbH announced today that the companies have signed a letter of intent to collaborate on a program to develop families of innovative new cattle and equine vaccines based on Syntro's "viral vector" technology.
 The multi-year development program is expected to cost $6-7 million and will be funded by the Hoechst companies.
 Syntro and Hoechst-Roussel Agri-Vet Company announced in March 1991 a similar agreement to develop a family of poultry vaccines. In September 1991 Hoechst Veterinar GmbH acquired European marketing rights to a genetically designed cattle vaccine that is in the final stages of development by Syntro.
 Syntro is a biotechnology company engaged in the research, development and commercialization of genetically designed vaccines for the animal health market.
 Hoechst-Roussel Agri-Vet Company is part of the Life Sciences Group of Hoechst Celanese Corporation of Somerville, N.J. Hoechst Veterinar GmbH of Munich, Germany, is a member of the Hoechst AG of Frankfurt, Germany, group of companies. Hoechst manufactures and markets a broad line of animal health products and is the seventh largest supplier of animal health products worldwide.
 -0- 2/19/92
 /CONTACT: Dr. J. Donald Todd or William J. Davies of Syntro, 913-888-8876, or Andrea Stine of Hoechst-Roussel Agri-Vet Co., 908-231-3752/
 (SYNT) CO: Syntro Corporation ST: Minnesota IN: SU:


KH -- MN002 -- 0327 02/19/92 10:04 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 19, 1992
Words:241
Previous Article:CONRAIL BOARD DECLARES DIVIDEND OF $.45 CASH PAYABLE MARCH 16
Next Article:NORDSON DIRECTORS DECLARE SECOND QUARTER 1992 DIVIDEND
Topics:


Related Articles
SYNTRO REPORTS FOURTH QUARTER PROFIT AND IMPROVED OPERATING RESULTS FOR FISCAL 1991
BAYER TO MARKET SYNTRO VACCINE IN EUROPE
HOECHST & SYNTRO EXPAND COLLABORATION TO DEVELOP VACCINES
HOECHST & SYNTRO EXPAND COLLABORATION TO DEVELOP VACCINES
SYNTRO VIRAL VECTOR VACCINE APPROVED FOR FINAL TESTING
SYNTRO REPORTS PRELIMINARY FINANCIAL RESULTS
MALLINCKRODT TO MAKE TENDER OFFER FOR SYNTRO CORPORATION STOCK
MALLINCKRODT TO MAKE TENDER OFFER FOR SYNTRO CORPORATION STOCK
Hoechst Roussel Vet Drops Suit Against Mallinckrodt Inc., J. P. Morgan
Hoechst Roussel Vet and Central Garden and Pet Company Sign Memorandum Of Understanding for Joint Development, Marketing and Distribution

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters